The ID Pipeline: FDA Activity From the Week of January 12, 2020

Here is a look at infectious disease-related US Food and Drug Administration (FDA) news from the week of January 12, 2020.

Novavax Granted Fast Track Designation for NanoFlu Recombinant Quadrivalent Vaccine Candidate in Older Adults

Novavax, Inc. has announced that the FDA granted Fast Track Designation for NanoFlu, a recombinant quadrivalent vaccine candidate adjuvanted with Matrix-M, in adults 65 years of age and older.

An ongoing Phase 3 clinical trial will assess the immunogenicity and safety of NanoFlu relative to the quadrivalent formulation Fluzone. Top-line clinical data is expected by the end of 2020 Q1.

Read the full press release here.